GlassScriptPhysician profile
Ann W Meade
NPI 1134180391
$2,874.81
in general payments reported to CMS, 2019-2025
49 companies · $602 in 2025
The $602 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $137 · 2021: $274 · 2022: $223 · 2023: $511 · 2024: $688 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $544.94 | 2019-2025 | |
| Novo Nordisk INC | $278.05 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Pfizer INC. | $233.99 | 2023-2025 | |
| Boston Scientific Corporation | $231.28 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $106.70 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $102.87 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $91.84 | 2023-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $86.41 | 2022-2025 | Spravato |
| Amgen INC. | $83.09 | 2019-2025 | Evenity |
| Lundbeck LLC | $78.90 | 2024 | Vyepti |
| Astellas Pharma US INC | $75.05 | 2019-2025 | Veozah |
| Eisai INC. | $67.42 | 2019-2024 | |
| Inspire Medical Systems, INC. | $62.94 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $57.99 | 2022 | |
| Amarin Pharma, INC. | $54.73 | 2020-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Meade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.